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Abstract
Introduction: Enterococcus species are associated with an increased morbidity in intraabdominal infections (IAI).
However, their impact on mortality remains uncertain. Moreover, the influence on outcome of the appropriate or
inappropriate status of initial antimicrobial therapy (IAT) is subjected to debate, except in septic shock. The aim of
our study was to evaluate whether an IAT that did not cover Enterococcus spp. was associated with 30-day mortality
in ICU patients presenting with IAI growing with Enterococcus spp.
Material and methods: Retrospective analysis of French database OutcomeRea from 1997 to 2016. We included all
patients with IAI with a peritoneal sample growing with Enterococcus. Primary endpoint was 30-day mortality.
Results: Of the 1017 patients with IAI, 76 (8%) patients were included. Thirty-day mortality in patients with inadequate
IAT against Enterococcus was higher (7/18 (39%) vs 10/58 (17%), p = 0.05); however, the incidence of postoperative
complications was similar. Presence of Enterococcus spp. other than E. faecalis alone was associated with a significantly
higher mortality, even greater when IAT was inadequate. Main risk factors for having an Enterococcus other than E.
faecalis alone were as follows: SAPS score on day 0, ICU-acquired IAI, and antimicrobial therapy within 3 months prior
to IAI especially with third-generation cephalosporins. Univariate analysis found a higher hazard ratio of death with an
Enterococcus other than E. faecalis alone that had an inadequate IAT (HR = 4.4 [1.3–15.3], p = 0.019) versus an adequate
IAT (HR = 3.1 [1.0–10.0], p = 0.053). However, after adjusting for confounders (i.e., SAPS II and septic shock at IAI
diagnosis, ICU-acquired peritonitis, and adequacy of IAT for other germs), the impact of the adequacy of IAT was no
longer significant in multivariate analysis. Septic shock at diagnosis and ICU-acquired IAI were prognostic factors.
Conclusion: An IAT which does not cover Enterococcus is associated with an increased 30-day mortality in ICU patients
presenting with an IAI growing with Enterococcus, especially when it is not an E. faecalis alone. It seems reasonable to
use an IAT active against Enterococcus in severe postoperative ICU-acquired IAI, especially when a third-generation
cephalosporin has been used within 3 months.
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Introduction
Intra-abdominal infections (IAI) represent the second
most common cause of infection in the ICU [1]. Indeed,
they are complicated with septic shock in 40% of cases
[2]. Despite improvements in sepsis management, mor-
tality remains high up to 40% in nosocomial IAI [3, 4].
The primary treatment of IAI combines early source
control and adequate antimicrobial therapy.
The incidence of Enterococci in IAI is 5 to 20% in
community-acquired IAI and 30 to 40% in nosocomial
IAI [5]; however, the pathogenicity of Enterococci in IAI
is debatable. According to Dupont, Koch, and Fisher,
Enterococcus might express virulence factors and might
synergize with other bacteria like Escherichia coli and
anaerobes [6–8]. It has been clearly demonstrated that
Enteroccoci are associated with proinflammatory re-
sponses, greater clinical disease burden, and shock [9–
11]. So far, all authors agree with an increase in morbid-
ity (septic shock, higher APACHE 2, and Sequential
Organ Failure Assessment (SOFA) scores, higher post-
operative infection scores, longer duration of mechanical
ventilation and vasopressors, more relaparotomies), but
the impact of Enterococcus on mortality is unclear [12–
16]. Some studies found that the presence of Enterococci
on peritoneal samples is a predictive factor for death
[17–19] whereas others did not [20, 21].
Currently, the impact on prognosis of early antimicro-
bial therapy against Enterococcus spp. is not known and
the indication of an initial empiric anti-enterococcal
therapy differs among recommendations. Thus, the aim
of our study was to compare the role of appropriate ver-
sus inappropriate antimicrobial therapy on 30-day mor-
tality in ICU patients with IAI positive for Enterococcus.
Material and methods
This study was a retrospective data analysis from the
OUTCOMEREA database (OutcomeRea®).
Data were prospectively collected daily by senior physi-
cians with research assistants in the participating ICUs. All
codes and definitions were established prior to study initi-
ation and have been previously described [22]. We collected
delay between hospitalization, diagnosis, and surgery.
Patients’ age, sex, and McCabe score were recorded.
Severity of illness was evaluated on the first ICU day
using the Simplified Acute Physiology Score (SAPS II),
Sequential Organ Failure Assessment (SOFA) score, and
Glasgow Coma Scale (GCS) score. Knaus’ scale defini-
tions were used to record preexisting chronic organ fail-
ures including respiratory, cardiac, hepatic, renal, and
immune system failures [23, 24]. Admission category
(medical, scheduled surgery, or unscheduled surgery),
admission diagnosis (cardiac, respiratory, or neurological
failure, infection, and other), invasive procedures (arter-
ial or venous central catheter, Swan-Ganz catheter, or
endotracheal intubation), and treatment of organ failures
(inotropic support, hemodialysis, and mechanical venti-
lation) and ICU-acquired infections, bacteriological sam-
ples, and daily antimicrobial therapy were also collected.
Data collected from hospitalization records were as
follows: risk factors for healthcare-associated infections,
antimicrobial therapy within the 3 months prior to ICU
admission (particularly with cephalosporins), date of
diagnosis of IAI according to clinical, biological and
radiological findings, anatomical origin of IAI, localized
or generalized type of IAI, community-acquired or noso-
comial infection, and pathophysiological mechanisms.
We also collected delay between diagnosis according to
clinical, biological, and radiological findings and surgery,
initial and adapted antimicrobial therapy, Enterococcus
species, sensibility to antimicrobial therapy, appropriate
or inappropriate type of antimicrobial therapy against
Enterococcus species, day of appropriate antimicrobial
therapy for Enterococcus species and other microorgan-
isms, surgical complications, need for redo laparotomy
or percutaneous drainage, and development of tertiary
peritonitis.
Ethical issue
The database is in accordance with French legislation con-
cerning biomedical research. Patients or their family gave
authorization for collection, conservation, and use of their
personal anonymized data. Authorizations were obtained
from the CNIL (Commission Nationale de l’Informatique
et des Libertés), the CCTIRS (Comité consultatif sur le
traitement de l’information en matière de recherche), and
the Rhône-Alpes-Auvergne Institutional Review Board.
Inclusion criteria
Adult patients over 18 years old presenting with commu-
nity-acquired or nosocomial IAI with a peritoneal sample
growing with Enterococcus spp. and who were admitted to
the ICU between 1997 and 2016 were included.
Non-inclusion criteria
Patients presenting superinfection of necrotizing pan-
creatitis, missing data either on the Enterococcus species
or on the antimicrobial therapy, and samples coming
from drains in the postoperative period were excluded.
Definition
Enterococcus IAI was defined as an IAI which required sur-
gery or percutaneous drainage and whose intraoperative
peritoneal sample was growing with Enterococcus. Day 0
(first day of the IAI) was defined as the day of surgery.
Intra-abdominal infections were nosocomial if they
appeared after more than 48 h of hospitalization or if
there were any risk factor of healthcare-associated in-
fection (hospitalization within 3 previous months,
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rehabilitation/long-care stay within the 30 previous
days, chronic dialysis or chemotherapy within 30 days,
or home-care within 30 days).
Enterococcus IAI were identified from the infectious
data recorded in the database. Medical records were
then accessed to confirm diagnosis and details of the
surgical procedure.
Initial antimicrobial therapy (IAT) was the antimicro-
bial therapy started on day 0 or day 1 after surgery. Anti-
microbial therapy was considered appropriate or
inappropriate according to the antibiogram when avail-
able. Otherwise, it was considered appropriate if it used
either a penicillin (A or ureido or carboxy) or a carba-
penem for Enterococcus faecalis, E. avium, or E. durans,
and vancomycin, linezolide, or tigecycline for Entero-
coccus faecium.
Delay between IAI (day 0) and appropriate antimicro-
bial therapy were extracted from the database separately
for Enterococcus spp. and other germs including yeasts.
Septic shock was defined according to the Surviving
Sepsis Campaign 4th edition (2016) [25]. For septic
shock at diagnosis, we considered septic shock criteria
within a 72-h period including the day preceding and
the day following IAI diagnosis.
Pneumoniae, other bacteremia (other than from
intraabdominal origin), and catheter-related bloodstream
infections were considered at diagnosis of IAI if they
were diagnosed within 48 h preceding the IAI diagnosis.
Outcomes
Primary outcome was 30-day mortality. Secondary out-
comes were surgical complications, redo laparotomies or
percutaneous drainage, postoperative infectious compli-
cations, and septic shock at day 30.
Statistical analysis
Patient characteristics were expressed in numbers (per-
centages) and median (interquartile interval) for qualita-
tive and quantitative variables, respectively. They were
compared using chi-squared and Mann-Whitney tests
respectively. The impact on day 30 mortality of Entero-
coccus species and inappropriate IAT on Enterococcus
species were assessed with univariate Cox models. Then,
multivariate Cox models adjusted on SAPS score on day
0, acquisition of peritonitis in ICU, and adequacy of IAT
on other germs were used. For every analysis, p < 0.05
was considered significant. All statistics were done using
SAS software (v 9.3, SAS Institute, Cary, NC, USA).
Results
Between 1997 and 2016, data of 1017 patients with IAI
were analyzed. Only 76 IAI with Enterococcus were in-
cluded (Additional file 1). Incidence of Enterococcus dif-
fered between centers (Additional file 2). Median [IQR]
age was 72 [59–78]. Fifty-seven percent of patients were
male. Median SAPS II score at day 0 was 52 [41–64].
Median time between admission in the hospital or in the
ICU and diagnosis of IAI was 8 [5–10] and 1 [1–4] days,
respectively. Eight (10.5%) patients had a community-ac-
quired IAI. Sixty-eight (89.5%) patients had a nosocomial
IAI, among them 2 were healthcare-associated IAI and 66
were hospital-acquired IAI. Two patients had a percutan-
eous drainage as an initial treatment, and 7 had a percu-
taneous drainage secondarily after an initial surgical
treatment. IAI characteristics are described in Table 1.
Germs associated with Enterococcus were as follows:
Gram-positive cocci (22%), Gram-negative bacilli (74%), an-
aerobes (20%), and yeasts (24%). IAI were associated with
Enterococcus bacteremia in 4 (5%) of cases. Eleven (14%) of
the 76 IAI were growing with only Enterococcus species.
Empirical antimicrobial therapies were piperacillin-tazobac-
tam (49%), carbapenems (33%), vancomycin (30%), and
third-generation cephalosporins (9%) in combination with
aminoglycosides in 70% of the cases. Initial empirical anti-
microbial therapy was inappropriate against Enterococcus
species isolated from peritoneal sample in 18 (23.7%) of
cases and against other germs in 12 (15.8%) of cases. Anti-
microbial therapy was modified to cover the recovered En-
terococci in 13 (72%) patients. Sensitivity to amoxicillin and
vancomycin was always available. There were 3 ESBL and
no VRE.
Table 2 compares patients who received adequate ver-
sus inadequate empirical therapy. The two groups were
similar for year of inclusion, age, gender, causes, and ori-
gins of IAI. Thirty-day mortality was significantly higher
in the group who received inadequate empiric anti-
microbial therapy against Enterococcus species identified
on peritoneal sample, but there was no difference in
postoperative complications. In this group, Enterococcus
spp. other than Enterococcus faecalis were more fre-
quently identified. Survival curves according to adequacy
of IAT against Enterococcus species identified on peri-
toneal sample are shown in Fig. 1.
Comparisons between patients with IAI growing with En-
terococcus spp. other than Enterococcus faecalis and Entero-
coccus faecalis alone are described in Table 2. Day 30
mortality was significantly higher in IAI growing with En-
terococcus spp. other than E. faecalis alone but there was no
difference in postoperative complications. Survival curves
according to Enterococcus species are shown in Fig. 2.
Impact on 30-day survival of the enterococcal species
and the adequacy of antibiotic therapy on enterococci is
displayed on Table 3.
Univariate analysis demonstrated that the identifica-
tion of species other than E. faecalis alone was associ-
ated with death and the mortality rate was greater if the
antibiotic therapy was inadequate against Enterococcus
spp. identified on peritoneal samples.
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However, after adjusting for confounders (i.e., SAPS II
and septic shock at IAI diagnosis, ICU-acquired periton-
itis, and adequacy of antibiotic therapy for other germs),
the impact of the adequacy of antimicrobial therapy was
no longer significant (Table 3). The impact of culturing
enterococci other than E. faecalis remained a poor prog-
nosis (HR = 2.283 [0.730–7.141], p = 0.156). A septic
shock at IAI diagnosis and an ICU-acquired IAI were as-
sociated with death regardless of the adequacy of IAT
and Enterococcus species.
Survival curves according to adequacy of IAT on
germs other than Enterococcus species identified on peri-
toneal sample are shown in Additional file 3.
Neither adequacy of IAT nor Enterococcus species were
associated with redo laparotomy on day 30 or percutan-
eous drainage in both univariate and multivariate analyses.
Discussion
In a large cohort of severe peritonitis with enterococci ad-
mitted in the ICU, we found that inadequate IAT against
Enterococcus spp. was associated with increased 30-day
mortality. We also found that Enterococcus spp. other than
E. faecalis alone were more frequent in cases of previous
therapy with third-generation cephalosporins in the past
3months and in ICU-acquired peritonitis. It was associ-
ated with inadequate IAT and a poorer prognosis.
Intraabdominal infections growing with Enterococcus
are associated with a worse prognosis. Theunissen et al.
showed that presence of Enterococci is a predictive factor
for death in both nosocomial and community-acquired
IAI and is independently associated with mortality (OR
3.88 (1.05–14.28) p = 0.044) [19]. In our study, the large
majority of IAI was nosocomial (90%) and mortality was
high (22% in the whole population and 39% in the in-
appropriate first antimicrobial therapy group). It was com-
parable with previously published data: 39% in
Montravers et al. study (mainly postoperative IAI with
multidrug-resistant bacteria), 25% in Sotto et al. (ICU
IAI), and 25% in Theunissen et al. (40% of nosocomial
IAI) [17, 19, 26]. Recently, Freedberg et al. found in a co-
hort of 301 medical ICU patients that VRE colonization
and Enterococcus domination were both associated with
death or all-cause infection at 30 days (aHR 1.46, 95% CI
1.06–2.00 and aHR 1.47, 95% CI 1.00–2.19, respectively)
after adjusting for severity of illness [27].
We found that an inappropriate IAT against Entero-
coccus spp. identified on peritoneal samples was associated
with a higher 30-day mortality. The only prospective ran-
domized trial that compared treatment with antimicrobial
therapy active or inactive against Enterococcus (penicillin
vs cephalosporin) concluded no differences between both
groups [28]. This study included only non-severe commu-
nity-acquired IAI (median APACHE scores 10 and 9); the
number of IAI growing with Enterococcus was very low (6
Table 1 Population characteristics. Results expressed in
numbers (percentages) except *median and interquartile
interval [1st–3rd]. IAI intraabdominal infection
Variables All IAI with
Enterococcus
spp. (n = 76)
Age (years)* 71.7 [59.0–78.1]
Gender (M/F) 43/33
Day 0 SAPS score* 48 [37–57]
Immunocompromised status 20 (26.3%)
Hospital admission-IAI time* 8 [2–18]
ICU admission-IAI time* 1 [1–4]
IAI diagnosis-surgery time 0 [0–0]
E. faecium 28 (36.8%)
E. faecalis 46 (60.5%)
Other Enterococcus spp. 9 (11.8%)
ICU acquired 24 (31.6%)
Nosocomial 68 (89.5%)
Postoperative 53 (69.7%)
Enterococcal bacteremia 4 (5.3%)
Septic shock at time of IAI diagnosis 53 (69.7%)
Source control
Surgery 74 (97.4%)
Percutaneous drainage 2 (2.6%)
IAI anatomical origin
Colon 32 (42.7%)
Small intestine 19 (25.3%)
Hepatobiliary 12 (16%)
Gastroduodenal 8 (10.7%)
Pathophysiology of IAI
Perforation 22 (28.9%)
Intraabdominal abscess 27 (35.5%)
Fistula 26 (34.2%)
Necrosis 19 (25.0%)
Surgical complications 35 (46.1%)
Intraabdominal abscess 20 (26.3%)
Wound infection 19 (25.0%)
Fistula 8 (10.5%)
Suture line disruption 2 (2.6%)
Evisceration 1 (1.3%)
Relaparotomy or percutaneous drainage at day 30 23 (30.3%)
IAI-relaparotomy or IAI-percutaneous drainage time
(days)*
10 [6–20]
Tertiary peritonitis 16 (21.3%).
Postoperative infectious complications at day 30 24 (31.6%)
Septic shock at day 30 44 (57.9%)
Mortality at day 30 17 (22.4%)
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over 110 peritonitis) [28]. However, in a population of 200
postoperative IAI among which 42 were growing with En-
terococcus, Sitges-Serra et al. found that mortality was
higher when IAT did not cover these Enterococcus (21%
vs 4%, p < 0.001) [14]. In Enterococcus bacteremia, early
use of anti-Enterococcus antimicrobial therapy within 48 h
is a protective factor against death [29].
Several studies have evaluated the impact on mortality of
the adequacy of an initial empiric antimicrobial therapy for
all peritoneal germs in general (not only for Enterococcus).
Sotto, Mosdell, Montravers, and Sturkenboom did not find
any difference [17, 20, 30, 31]. However, Sotto studied ICU
IAI but the numbers were small in the inappropriate
antimicrobial therapy group (14 patients) and the three
other studies included mainly patients with community-ac-
quired and non-severe IAI. Nevertheless, Montravers’
study on postoperative IAI growing with multiresistant
bacteria (2009) and Harbarth’s study on severe sepsis and
septic shock showed that an inappropriate IAT was an in-
dependent risk factor of death in IAI [26, 32]. Thus, it
seems that an appropriate IAT has an impact on mortality
especially in severe postoperative IAI with septic shock.
However, we did not find more redo laparotomies or
percutaneous drainages or infectious complications at
day 30 when IAT was inappropriate. Other studies
showed that an inappropriate IAT against all microbials
Table 2 Comparison between patients who received an appropriate initial antimicrobial therapy against Enterococcus species
isolated from peritoneal sample versus patients who did not and between the groups E. faecalis alone and Enterococcus other than
E. faecalis alone. Results expressed in numbers (percentages) apart from *median and interquartile interval [1st–3rd]. **Diagnosed
within 48 h preceding IAI diagnosis. IAI intraabdominal infections
Variables Initial antimicrobial
therapy inactive against
Enterococcus (n = 18)
Initial antimicrobial
therapy active against
Enterococcus (n = 58)
p Enterococcus other
than E. faecalis
alone (n = 34)
E. faecalis alone
without other
Enterococcus species
(n = 42)
p
Antimicrobial therapy use < 3months prior
to IAI
9 (50.0) 34 (58.6) 0.519 26 (76.5) 17 (40.5) 0.002
Third-generation cephalosporin use
< 3 months prior to IAI
6 (33.3) 7 (12.1) 0.036 9 (26.5) 4 (9.5) 0.051
Hospital admission-IAI time* 4 [2–7] 10 [3–22] 0.016 10 [3–24] 6 [2–13] 0.104
ICU admission-IAI time* 1 [1–4] 1 [1–5] 0.622 2 [1–7] 1 [1–1] 0.024
IAI diagnosis-surgery time* 0 [0–0] 0 [0–0] 0.728 0 [0–0] 0 [0–0] 0.986
Postoperative IAI 7 (38.9) 18 (79.3) 0.001 23 (67.6) 30 (71.4) 0.721
ICU-acquired IAI 8 (44.4) 16 (27.6) 0.179 15 (44.1) 9 (21.4) 0.034
SAPS on day 0* 56.5 [39–63] 45.5 [37–55] 0.029 50.0 [39–60] 45.5 [36–54] 0.051
Day 0 vasopressor use 14 (77.8) 40 (69.0) 0.471 27 (79.4) 27 (64.3) 0.148
Septic shock at diagnosis 15 (83.3) 38 (65.5) 0.151 26 (76.5) 27 (64.3) 0.250
Pneumonia** 1 (5.6) 1 (1.7) 0.375 1 (2.9) 1 (2.4) 0.879
Other bacteremia** 2 (11.1) 4 (6.9) 0.562 2 (5.9) 4 (9.5) 0.558
Catheter-related bloodstream infection** 0 (0) 3 (5.2) 0.151 1 (2.9) 2 (4.8) 0.685
Adequate initial antimicrobial therapy
against other germs
14 (77.8) 50 (86.2) 0.392 28 (82.4) 36 (85.7) 0.689
Inadequate initial antimicrobial therapy
against identified Enterococcus
18 (100) 0 (0) <
0.001
22 (64.7) 36 (85.7) 0.032
Vancomycin in initial antimicrobial
regimen
1 (5.6) 22 (37.9) 0.009
E. faecium isolated in peritoneal sample 11 (61.1) 17 (29.3) 0.015
E. faecalis isolated in peritoneal sample 8 (44.4) 38 (65.5) 0.110
Other Enterococcus isolated in peritoneal
sample
2 (11.1) 7 (12.1) 0.913
Day 30 surgical complications 8 (44.4) 27 (46.6) 0.875 15 (44.1) 20 (47.6) 0.761
Day 30 relaparotomy or percutaneous
drainage
4 (22.2) 19 (32.8) 0.395 7 (20.6) 16 (38.1) 0.099
Day 30 infectious complications 7 (38.9) 17 (29.3) 0.445 12 (35.3) 12 (28.6) 0.531
Day 30 mortality 7 (38.9) 10 (17.2) 0.054 12 (35.3) 5 (11.9) 0.015
Morvan et al. Critical Care          (2019) 23:307 Page 5 of 10
Fig. 1 Survival according to adequacy of initial antimicrobial therapy on Enterococcus species identified on peritoneal sample (Kaplan-Meier plot)
Fig. 2 Survival according to Enterococcus species (Kaplan-Meier plot)
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found on the peritoneal sample was associated with a
higher morbidity both in community-acquired and noso-
comial IAI in terms of length of stay, wound infection,
redo laparotomies, and postoperative complications [14,
26, 30, 31, 33, 34].
An inadequate IAT against Enterococcus spp. identified
on peritoneal samples was associated with postoperative
IAI, time between hospital admission and IAI, antimicro-
bial therapy with third-generation cephalosporins within
the 3months prior to IAI, IAI with E. faecium or any En-
terococcus species other than E. faecalis, and an IAT that
did not include vancomycin. This implies that adequacy of
IAT was associated with the use of vancomycin. WSES
recommendations are to cover Enterococcus in postopera-
tive IAI but not in community-acquired IAI [35]. For
IDSA, “empiric anti-enterococcal therapy is recommended
for patients with healthcare-associated IAI, particularly
those with postoperative infection, those who have previ-
ously received cephalosporins or other antimicrobial
agents selecting for Enterococcus species, immunocom-
promised patients, and those with valvular heart disease
or prosthetic intravascular materials”. “Anti-enterococcal
therapy should be directed against Enterococcus faecalis”,
and “antibiotics that can potentially be used … include
ampicillin, piperacillin-tazobactam or vancomycin” [36].
In multivariate analysis, adequacy of IAT on Entero-
coccus species was no longer independently associated
with survival after adjustment on adequacy of IAT on
other germs, time of onset of IAI (ICU-acquired IAI),
SAPS score, and septic shock at time of diagnosis. How-
ever, septic shock at diagnosis and ICU-acquired IAI
were risk factors for death regardless of the Enterococcus
species and adequacy of IAT. It has been shown multiple
times in the literature that an IAI with septic shock has
a higher mortality rate than an IAI without septic shock
[2, 20, 37] and our study confirms this finding.
Finally, we found a difference in 30-day mortality de-
pending on Enterococcus species: E. faecalis alone vs En-
terococcus other than E. faecalis alone (mostly E. faecium).
In univariate analysis, we found a higher hazard ratio for
death with an Enterococcus other than E. faecalis alone
that had been initially inadequately treated compared to
adequately treated; this suggests that the species of Entero-
coccus had a greater impact than adequacy of IAT on
Table 3 Univariate and multivariate models evaluating the impact of Enterococci spp. and adequacy of initial antimicrobial therapy
on enterococci on day 30 mortality, with adjustment on SAPS score and septic shock at diagnosis, acquisition of IAI in ICU, and
adequacy of initial antimicrobial therapy on other germs. *As interaction term between adequate therapy and other than E. faecalis
alone IAI was significant, we created a variable with three classes, E. faecalis IAI was the reference
Parameters HR CI 95% p value
Univariate models
No E. faecalis alone 3.545 1.247 10.079 0.018
Inappropriate IAT on Enterococcus spp. 2.612 0.991 6.883 0.052
No E. faecalis alone + inadequate IAT on Enterococcus spp.* 4.427 1.277 15.344 0.019
No E. faecalis alone + adequate IAT on Enterococcus spp.* 3.106 0.985 9.796 0.053
Multivariate models
Inappropriate IAT on Enterococcus spp. 1.445 0.498 4.195 0.498
SAPS on day 0 1.003 0.964 1.043 0.893
ICU-acquired peritonitis 3.282 1.191 9.041 0.021
Adequate IAT on other germs 1.364 0.299 6.221 0.689
Septic shock at diagnosis 11.828 1.451 96.396 0.021
No E. faecalis alone 2.283 0.730 7.141 0.156
SAPS on day 0 1.003 0.964 1.043 0.890
ICU-acquired peritonitis 2.613 0.898 7.605 0.078
Adequate IAT on other germs 1.469 0.312 6.927 0.627
Septic shock at diagnosis 11.101 1.386 88.887 0.023
No E. faecalis alone + inadequate IAT on Enterococcus spp. 2.290 0.551 9.519 0.254
No E. faecalis alone + adequate IAT on Enterococcus spp. 2.281 0.690 7.535 0.176
SAPS on day 0 1.003 0.964 1.043 0.890
ICU-acquired peritonitis 2.611 0.859 7.937 0.091
Adequate IAT on other germs 1.470 0.307 7.031 0.629
Septic shock at diagnosis 11.094 1.371 89.776 0.024
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survival. Risk factors of having an Enterococcus other than
E. faecalis alone in univariate analysis were SAPS score on
day 0, Cardio SOFA score on ICU admission, time be-
tween ICU admission and IAI, ICU-acquired IAI, anti-
microbial therapy within the 3months prior to IAI
especially with third-generation cephalosporins, anti-
microbial therapy prior to relaparotomy in postoperative
IAI, and an inadequate IAT. Previous studies on entero-
coccal bacteremia found that SAPS score, prior antimicro-
bial therapy exposure (mainly penicillin and third-
generation cephalosporins, but also carbapenems, amino-
glycosides, and clindamycin), hematologic malignancies
and neutropenia, current corticosteroid therapy, organ
dysfunction, gastrointestinal disease (vs genitourinary
disease), and nosocomial acquisition were risk factors for
E. faecium isolation (vs E. faecalis) [38–42]. Some studies
found a higher mortality with E. faecium than with E.
faecalis bloodstream infections [38, 40, 42]. Our findings
are consistent with those studies. Enterococcus spp.,
especially other than E. faecalis, are associated with a
poorer prognosis in IAI and their presence is often associ-
ated with a previous antimicrobial therapy within the 3
months prior to IAI and especially with third-generation
cephalosporins.
Our study has several limits
First, the number of patients especially in the inappro-
priate IAT group was low. We can explain the small
number of patients by the very selected population we
studied. But to our knowledge, this is the second largest
cohort of IAI growing with Enterococcus after Kaffarnik
et al.’s cohort [21]. However, because the population is
highly selected, the results of our study should only be
taken as an exploratory approach and further studies are
needed to confirm those results.
Second, this is a retrospective study although data was
extracted from a multicentric national database in which
data are collected prospectively. Presence of missing data
led us to read medical records, but since almost one
third of medical records were not available, we had to
exclude nearly a hundred of patients. Information bias
cannot be excluded especially about previous antimicro-
bial therapy before hospital admission.
Third, we had no prospectively collected data about
the quality of source control. All patients had either sur-
gery or percutaneous drainage. Yet it is known that a
good quality of source control is associated with a re-
duction in mortality in IAI [43]. Therefore, it is a limita-
tion to conclude on mortality without information about
source control quality. However, evaluation would have
been subjective since there is no validated questionnaire
to evaluate source control quality apart from the check-
list recommended by Solomkin et al. to be done at the
end of surgery or percutaneous drainage [44].
Finally, data collection was extended over 20 years.
Both surgery and critical care evolved during this period.
Critical care management improved widely for the last
10 years which led to a better prognosis in sepsis. How-
ever, there were no difference in years of inclusion be-
tween groups.
Conclusion
We found that inadequacy of IAT on Enterococcus spe-
cies identified on peritoneal sample was associated with
a worse 30-day survival especially when it was not an E.
faecalis alone. This inadequacy was partly due to the ab-
sence of vancomycin in the empiric antibiotic regimen.
These results should encourage the physician to use an
antimicrobial regimen active against non-faecalis Entero-
coccus (like vancomycin) in severe, postoperative, ICU-
acquired IAI, especially when an antimicrobial therapy
with third-generation cephalosporins has been used
within 3 months preceding IAI. Our study also suggests
that IAI with non E. faecalis Enterococci have a poorer
prognosis than IAI with E. faecalis alone. It would be in-
teresting to conduct a prospective and larger study to
confirm these results.
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